---
layout: default
title: Activated Charcoal Arginine Bos Taurus Hypothalamu
parent: 僅模型預測 (L5)
nav_order: 200
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Arginine Bos Taurus Hypothalamu
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex (28 Components): Insufficient Data for TxGNN Repurposing Analysis

## One-Sentence Summary

This product is a complex 28-ingredient mixture comprising homeopathic botanical extracts, animal organ fractions, amino acids, mineral salts, and CoQ10 (ubidecarenone), with no regulatory authorizations in the US and no original approved indication on record. The TxGNN model was unable to generate repurposing predictions for this product, as the multi-ingredient homeopathic formulation cannot be resolved to a single DrugBank entity required for knowledge graph mapping. No supporting clinical trials or literature evidence was retrieved for a repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record |
| Predicted New Indication | None — TxGNN produced no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — not applicable; no output generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why TxGNN Could Not Process This Product

The TxGNN model requires a resolvable DrugBank ID as its entry point into the knowledge graph. This product contains 28 distinct ingredients spanning four categories:

**Homeopathic botanicals**: Chelidonium majus, Fucus vesiculosus, Lycopodium clavatum spore, Ornithogalum umbellatum, Phytolacca americana root, Quercus robur (nut and twig bark), Sinapis arvensis, Strychnos nux-vomica seed.

**Animal organ fractions (glandular/sarcode)**: Bos taurus hypothalamus, Sus scrofa pituitary gland, Sus scrofa placenta, oyster shell calcium carbonate.

**Amino acids and metabolic cofactors**: Arginine, cysteine, leucine, proline, serine, threonine, valine, ubidecarenone (CoQ10).

**Inorganic / excipient components**: Activated charcoal, graphite, magnesium phosphate dibasic trihydrate, potassium phosphate dibasic, sodium chloride, sodium phosphate dibasic heptahydrate, sucrose.

No unified DrugBank ID could be assigned to the mixture as a whole, and no single active pharmaceutical ingredient (API) dominates the formulation. As a result, the knowledge graph traversal step — the prerequisite for TxGNN scoring — could not be executed. The product is therefore outside the current scope of the TxGNN drug repurposing pipeline.

---

## US Market Information

No regulatory authorizations found. This product has no NDA, BLA, or OTC monograph registrations in the US.

---

## Safety Considerations

Please refer to the package insert for safety information. No DDI data, contraindications, or key warnings were retrievable from available databases for this multi-ingredient formulation.

> **Note on Strychnos nux-vomica**: In conventional pharmacology, nux vomica seed contains strychnine and brucine — both potent CNS stimulants with a narrow therapeutic index. In homeopathic formulations, the ingredient is typically used at high dilutions where pharmacological activity is debated. If this product is used at measurable concentrations of nux vomica alkaloids, strychnine toxicity (convulsions, muscle spasm, respiratory failure) must be considered.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This product is a complex homeopathic mixture with no DrugBank ID, no US regulatory approval, no approved indication, and no TxGNN-generated repurposing candidate. The pipeline cannot be meaningfully applied to this formulation in its current configuration.

**To proceed, the following is needed:**

- **Identify the intended indication**: Clarify what clinical or wellness purpose this product is marketed for in its country of origin, so a relevant comparator can be established.
- **Determine if a single API can be isolated**: If one ingredient (e.g., ubidecarenone / CoQ10) is the putative active component, run a separate TxGNN analysis on that ingredient alone using its DrugBank ID (DB09107).
- **Regulatory classification review**: Determine whether this product is classified as a homeopathic drug, dietary supplement, or OTC product in the target market — this determines which regulatory pathway applies.
- **Obtain package insert or label**: Required to complete the safety profile, approved indication, and contraindications fields (Data Gap DG001).
- **Reformulate pipeline inputs**: The current evidence collection pipeline is designed for single-entity small molecules. A multi-ingredient workflow (e.g., ingredient-by-ingredient analysis followed by combination scoring) would need to be established before TxGNN repurposing can proceed.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

